MedTrace Logo

Taltz in Combination With Enstilar for Psoriasis

NCT04372277 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-05-04

No results posted yet for this study

Summary

Enstilar in combination with Taltz for plaque psoriasis.

Conditions

Interventions

DRUG

Enstilar

topical Enstilar foam

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2021-03-01
Completion
2021-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04372277 on ClinicalTrials.gov